Health Trials

ER-Negative Breast Cancer

2

Review clinical trials related to ER-Negative Breast Cancer. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

The purpose of this study is to test the safety and effectiveness of the study drug datopotamab deruxtecan in participants with metastatic breast cancer that has spread to the brain. The name of the study drug used in this research study is: Datopotamab deruxtecan (a type of antibody-drug conjugate)

Participants needed: 58
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Nancy Lin, MDUpdated: Aug 6, 2026Locations: 3
Eligibility criteria

Metastatic breast cancer that is pathologically confirmed to be HER2-negative ac... [+20]

Visceral crisis or impending visceral crisis [+22]

Read more
Status: Recruiting

Sacituzumab Govitecan In TNBC

This research study is studying to evaluate sacituzumab govitecan for individuals with localized triple negative breast cancer (TNBC) The names of the study drugs involved in this study is: * Sacituzumab govitecan (SG) * Pembrolizumab (combination therapy with SG)

Participants needed: 239
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Massachusetts General HospitalUpdated: Jul 17, 2026Locations: 5
Eligibility criteria

Female or male patients ≥ 18 years of age. [+16]

Participants currently receiving systemic therapy for any malignancy or having r... [+7]

Read more